- Home
- TNXP vs BRT Comparison
TNXP vs BRT Comparison
Compare TNXP & BRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- BRT
- Stock Information
- Founded
- TNXP 2007
- BRT 1972
- Country
- TNXP United States
- BRT United States
- Employees
- TNXP N/A
- BRT N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- BRT Real Estate Investment Trusts
- Sector
- TNXP Health Care
- BRT Real Estate
- Exchange
- TNXP Nasdaq
- BRT Nasdaq
- Market Cap
- TNXP 335.6M
- BRT 288.5M
- IPO Year
- TNXP N/A
- BRT N/A
- Fundamental
- Price
- TNXP $26.54
- BRT $15.45
- Analyst Decision
- TNXP Buy
- BRT Strong Buy
- Analyst Count
- TNXP 1
- BRT 1
- Target Price
- TNXP $70.00
- BRT $21.00
- AVG Volume (30 Days)
- TNXP 1.9M
- BRT 27.1K
- Earning Date
- TNXP 08-11-2025
- BRT 11-06-2025
- Dividend Yield
- TNXP N/A
- BRT 6.38%
- EPS Growth
- TNXP N/A
- BRT N/A
- EPS
- TNXP N/A
- BRT N/A
- Revenue
- TNXP $9,831,000.00
- BRT $98,407,000.00
- Revenue This Year
- TNXP $21.19
- BRT N/A
- Revenue Next Year
- TNXP $722.94
- BRT $4.51
- P/E Ratio
- TNXP N/A
- BRT N/A
- Revenue Growth
- TNXP N/A
- BRT 2.46
- 52 Week Low
- TNXP $6.76
- BRT $14.17
- 52 Week High
- TNXP $130.00
- BRT $20.22
- Technical
- Relative Strength Index (RSI)
- TNXP 32.47
- BRT 49.08
- Support Level
- TNXP $34.50
- BRT $15.40
- Resistance Level
- TNXP $29.70
- BRT $16.00
- Average True Range (ATR)
- TNXP 3.35
- BRT 0.36
- MACD
- TNXP -1.55
- BRT 0.02
- Stochastic Oscillator
- TNXP 4.29
- BRT 45.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.